Bank of America

The sterling corporate bond market maintained some, albeit low, momentum as UK coach operator National Express announced the mandate for a seven year issue in the currency on Thursday.

Valmet, the Finnish technological services company, has refinanced a €200m facility first signed in May 2013. The company swapped two of the original lenders with new banks.

Dis-Chem Pharmacies, one of the leading South African pharmacy chains, is preparing an IPO on the Johannesburg Stock Exchange to raise funds to expand its operations and reduce its debt.

Industrial and Commercial Bank of China’s New York branch was forced to scrap a 10 year portion of a dual tranche bond on Monday because of a disagreement with investors over what it should pay. But all was not lost, as the issuer decided to make the most of the demand for the shorter tenor, taking home $1bn in the end, writes Addison Gong.

China Resources Pharmaceutical Group, Samsung BioLogics and ZTO Express all have investors clamouring to join their IPOs, as they look to raise a combined $5.2bn.

China Resources Pharmaceutical Group has tightened the price range on its IPO, putting it on track to raise up to HK$14.8bn ($1.9bn), according to a banker on the deal.

The World Bank will on Thursday attempt to resurrect the 10 year part of the dollar curve, a sector that has had next to no benchmark issuance from top tier issuers in the second half of the year.

Bank of America Merrill Lynch has reshuffled the senior management of its debt capital markets and corporate banking teams in London.

Bayer has released the names of the banks in its $56.9bn loan for the acquisition of Monsanto, the jumbo deal tickets have bumped up some lenders in European league tables.

Food and drinks giant Nestlé has signed €10.5bn of loans to refinance five and one year deals. The company refinanced to secure a similar group of banks in both deals, according to one banker.

PNB Housing Finance and Varun Beverages are launching their IPOs in India next week to raise a combined Rp41.1bn ($616.9m).

China Resources Pharmaceutical Group is proving a hit with global investors, as its HK$15.7bn ($2.0bn) Hong Kong IPO is heavily oversubscribed, according to a banker at one of the leads.